KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Other Operating Expenses (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Other Operating Expenses data on record, last reported at $54.6 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 0.76% year-over-year to $54.6 million; the TTM value through Dec 2025 reached $207.0 million, down 47.04%, while the annual FY2025 figure was $207.0 million, 47.04% down from the prior year.
  • Other Operating Expenses reached $54.6 million in Q4 2025 per PCRX's latest filing, up from $48.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $216.4 million in Q3 2024 and bottomed at $35.2 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $65.2 million, with a median of $55.1 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: soared 278.01% in 2024, then plummeted 77.71% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $87.3 million in 2021, then grew by 14.96% to $100.4 million in 2022, then plummeted by 35.97% to $64.3 million in 2023, then decreased by 15.66% to $54.2 million in 2024, then rose by 0.76% to $54.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $54.6 million in Q4 2025, $48.2 million in Q3 2025, and $55.5 million in Q2 2025.